Literature DB >> 30219816

Serum Lipopolysaccharide-Binding Protein is Associated with Chronic Inflammation and Metabolic Syndrome in Hemodialysis Patients.

Paik Seong Lim1,2,3, Yu-Kang Chang4, Tsai-Kun Wu5.   

Abstract

BACKGROUND: In hemodialysis (HD) patients, impaired gut barrier and alteration in microbiota in the gut is thought to increase the risk of bacterial translocation and chronic inflammation. Lipopolysaccharide-binding protein (LBP) is an acute-phase reactant that mediates immune responses triggered by microbial products. Our aim is to investigate the relationship between circulating levels of LBP, and various metabolic and inflammatory markers in HD patients. Besides, we also aim to determine its relationship among -patients with different body mass index. PATIENTS AND METHODS: A total of 123 HD patients were stratified into three -tertiles, according to serum LBP level. The LBP and inflammatory markers were determined using immunoassay methods. A bioimpedance spectroscopy device was used for body composition measurement.
RESULTS: The serum levels of the two proinflammatory markers, high-sensitivity C-reactive protein (hsCRP) and interleukin (IL)-6, were significantly higher in patients in the upper tertile when compared with the rest of the tertiles. In HD patients, a significant positive correlation was found between serum LBP levels and CRP, IL-6, soluble CD14 (sCD14), and fasting blood glucose levels. Patients with metabolic syndrome and pre-existing cardiovascular disease had higher LBP levels than those without metabolic syndrome. Besides, obese patients were also associated with higher serum LBP levels. Multivariate regression analyses showed that IL-6 level was the strongest correlate of LBP level, followed by hsCRP level and sCD14.
CONCLUSIONS: Our study suggested that elevated plasma LBP was associated with metabolic syndrome and obesity. In addition, increased LBP level was correlated positively to markers of inflammation, and sCD14 levels.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Hemodialysis; Inflammation; Lipopolysaccharide-binding protein; Metabolic syndrome

Mesh:

Substances:

Year:  2018        PMID: 30219816     DOI: 10.1159/000492778

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  12 in total

1.  The strawberry-derived permeation enhancer pelargonidin enables oral protein delivery.

Authors:  Nicholas G Lamson; Katherine C Fein; John P Gleeson; Alexandra N Newby; Sijie Xian; Kyle Cochran; Namit Chaudhary; Jilian R Melamed; Rebecca L Ball; Kanika Suri; Vishal Ahuja; Anna Zhang; Adrian Berger; Dmytro Kolodieznyi; Brigitte F Schmidt; Gloria L Silva; Kathryn A Whitehead
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-09       Impact factor: 12.779

2.  Metabolite, protein, and tissue dysfunction associated with COVID-19 disease severity.

Authors:  Ali Rahnavard; Brendan Mann; Abhigya Giri; Ranojoy Chatterjee; Keith A Crandall
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

3.  Circulating 1,3-Beta-D-Glucan is Associated with Lung Function, Respiratory Symptoms, and Mediators of Matrix Degradation in Chronic Obstructive Pulmonary Disease.

Authors:  Matthew Gorgone; Deepti Singhvi; Seyed Mehdi Nouraie; Malcolm Finkelman; Yonglong Zhang; Jiantao Pu; Divay Chandra; Yingze Zhang; Georgios D Kitsios; Alison Morris; Frank C Sciurba; Jessica Bon
Journal:  Chronic Obstr Pulm Dis       Date:  2022-07-29

4.  Postprandial Endotoxin Transporters LBP and sCD14 Differ in Obese vs. Overweight and Normal Weight Men during Fat-Rich Meal Digestion.

Authors:  Fabienne Laugerette; Cécile Vors; Maud Alligier; Gaëlle Pineau; Jocelyne Drai; Carole Knibbe; Béatrice Morio; Stéphanie Lambert-Porcheron; Martine Laville; Hubert Vidal; Marie-Caroline Michalski
Journal:  Nutrients       Date:  2020-06-18       Impact factor: 5.717

Review 5.  The Effect of Dietary Fibre on Gut Microbiota, Lipid Profile, and Inflammatory Markers in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Authors:  Omorogieva Ojo; Osarhumwese Osaretin Ojo; Nazanin Zand; Xiaohua Wang
Journal:  Nutrients       Date:  2021-05-26       Impact factor: 5.717

6.  Systems Analysis of Gut Microbiome Influence on Metabolic Disease in HIV-Positive and High-Risk Populations.

Authors:  Abigail J S Armstrong; Kevin Quinn; Jennifer Fouquier; Sam X Li; Jennifer M Schneider; Nichole M Nusbacher; Katrina A Doenges; Suzanne Fiorillo; Tyson J Marden; Janine Higgins; Nichole Reisdorph; Thomas B Campbell; Brent E Palmer; Catherine A Lozupone
Journal:  mSystems       Date:  2021-05-18       Impact factor: 6.496

7.  Targeting ROS and cPLA2/COX2 Expressions Ameliorated Renal Damage in Obese Mice with Endotoxemia.

Authors:  Jia-Feng Chang; Jih-Chen Yeh; Chun-Ta Ho; Shih-Hao Liu; Chih-Yu Hsieh; Ting-Ming Wang; Shu-Wei Chang; I-Ta Lee; Kuo-Yang Huang; Jen-Yu Wang; Wei-Ning Lin
Journal:  Int J Mol Sci       Date:  2019-09-06       Impact factor: 5.923

8.  Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritis.

Authors:  Federica Ciregia; Dominique Baiwir; Gaël Cobraiville; Thibaut Dewael; Gabriel Mazzucchelli; Valérie Badot; Silvana Di Romana; Paschalis Sidiras; Tatiana Sokolova; Patrick Durez; Michel G Malaise; Dominique de Seny
Journal:  J Transl Med       Date:  2020-01-06       Impact factor: 5.531

9.  Serum sCD14, PGLYRP2 and FGA as potential biomarkers for multidrug-resistant tuberculosis based on data-independent acquisition and targeted proteomics.

Authors:  Jing Chen; Yu-Shuai Han; Wen-Jing Yi; Huai Huang; Zhi-Bin Li; Li-Ying Shi; Li-Liang Wei; Yi Yu; Ting-Ting Jiang; Ji-Cheng Li
Journal:  J Cell Mol Med       Date:  2020-09-23       Impact factor: 5.310

Review 10.  Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.

Authors:  Gracia Fahed; Laurence Aoun; Morgan Bou Zerdan; Sabine Allam; Maroun Bou Zerdan; Youssef Bouferraa; Hazem I Assi
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.